Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lorcaserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 18/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lorcaserin SCHEMBL29349440 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL170848 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL169382 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL5946555 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL1954700 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL171009 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL174046 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL16672993 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL174044 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL173899 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-8993750-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | claimed |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | claimed |
| US-8952197-B2 | Processes for the preparation of 5-HT2C receptor agonists | ARENA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-20130217676-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-08-22 | — | — | US | claimed |
| EP-2374796-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| EP-2363394-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | claimed |
| US-6953787-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | claimed |
| CN-109280030-B | Benzazaylalkyl aryl piperazine derivative and application thereof in preparing medicines | 江苏恩华药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9714225-B2 | Processes for the preparation of lorcaserin | CADILA HEALTHCARE LIMITED (IN) | 2017-07-25 | — | — | US | disclosed |
| US-9714225-B2 | Processes for the preparation of lorcaserin | CADILA HEALTHCARE LIMITED (IN) | 2017-07-25 | — | — | US | disclosed |
| US-20160280658-A1 | PROCESSES FOR THE PREPARATION OF LORCASERIN | CADILA HEALTHCARE LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280658-A1 | PROCESSES FOR THE PREPARATION OF LORCASERIN | CADILA HEALTHCARE LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2005003096-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1411881-A4 | 5HT sb 2C /sb RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1411881-A2 | 5HT sb 2C /sb RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030225057-A1 | 3-Benzoazepine derivatives | ARENA PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003086306-A2 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225057-A1 | 3-Benzoazepine derivatives | HTR2C, HTR1A, HTR3A | HTR2C 1/4885HTR2A 13/4885HTR2B 10/4885 |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2A 7/4885HTR2B 14/4885 |
| US-20160280658-A1 | PROCESSES FOR THE PREPARATION OF LORCASERIN | CEL, CMA1, NISCH | HTR2C 14/4885HTR2A 28/4885HTR2B 25/4885 |
| US-20130217676-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885 |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.